logo-loader
HealthPharma & Biotech
Amryt Pharma PLC

Amryt Pharma’s Lojuxta ‘bad’ cholesterol treatment to be made available in France in early 2019

The approval from French regulators means Lojuxta will soon be available in all five of the EU’s largest markets

Lojuxta is a treatment for Homozygous Familial Hypercholesterolaemia which causes high levels of ‘bad’ cholesterol
Lojuxta is a treatment for Homozygous Familial Hypercholesterolaemia which causes high levels of ‘bad’ cholesterol

Amryt Pharma PLC’s (LON:AMYT) flagship Lojuxta drug will soon be available in all five of the EU’s largest markets after French officials agreed to reimburse patients receiving the ‘bad’ cholesterol treatment.

The drug is expected to be made available to French patients suffering from the rare condition – known in the medical sphere as Homozygous Familial Hypercholesterolaemia (HoFH) – from early next year.

READ: Lojuxta to be made available on the NHS

The approval means that Lojuxta is available across all five of the EU's major markets – France, the UK, Italy, Germany and Spain.

“A clear aim in continuing the positive momentum in Lojuxta revenues is to ensure reimbursement in our core territories,” said chief executive Joe Wiley.

“Following closely on from our recent approval with the NHS in England, where we have already started treating patients, we are now very  pleased to be able to make Lojuxta available to adult HoFH patients in France.”

HoFH is a rare life-threatening disorder that causes abnormally high levels of low-density lipoprotein (LDL) cholesterol.

Clinical trials showed Lojuxta can reduce the production and uptake of this ‘bad’ cholesterol, helping sufferers to get their cholesterol levels down to acceptable levels.

Quick facts: Amryt Pharma PLC

Price: £1.41

Market: AIM
Market Cap: £71.04 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO

Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory Nealon tells Proactive: ''Our focus is to acquire, develop and commercialise products in the...

on 11/07/2016

2 min read